Early diagnosis of Alzheimer's disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts

Basit Öğe Kaydı
dc.authorid0000-0002-0860-0524
dc.contributor.authorRossini, Paolo Maria
dc.contributor.authorDi Iorio, Riccardo
dc.contributor.authorVecchio, F.
dc.contributor.authorAnfossi, Maria
dc.contributor.authorBabiloni, C.
dc.contributor.authorBozzali, M.
dc.contributor.authorBruni, Amalia Cecilia
dc.contributor.authorCappa, Stefano F.
dc.contributor.authorEscudero, Julien
dc.contributor.authorFraga, Francisco Jose
dc.contributor.authorGiannakopoulos, Panteleimon
dc.contributor.authorGüntekin, Bahar
dc.contributor.authorLogroscino, Giancarlo
dc.contributor.authorMarra, Camillo
dc.contributor.authorMiraglia, F.
dc.contributor.authorPanza, Francesco
dc.contributor.authorTecchio, F.
dc.contributor.authorPascual-Leone, Alvaro
dc.contributor.authorDubois, Bruno
dc.date.accessioned2020-07-28T08:04:11Z
dc.date.available2020-07-28T08:04:11Z
dc.date.issued2020
dc.departmentİstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Biyofizik Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Rektörlük, Rejeneratif ve Restoratif Tıp Araştırmaları Merkezi (REMER)
dc.description.abstractAlzheimer's disease (AD) is the most common neurodegenerative disease among the elderly with a progressive decline in cognitive function significantly affecting quality of life. Both the prevalence and emotional and financial burdens of AD on patients, their families, and society are predicted to grow significantly in the near future, due to a prolongation of the lifespan. Several lines of evidence suggest that modifications of risk-enhancing life styles and initiation of pharmacological and nonpharmacological treatments in the early stage of disease, although not able to modify its course, helps to maintain personal autonomy in daily activities and significantly reduces the total costs of disease management. Moreover, many clinical trials with potentially disease-modifying drugs are devoted to prodromal stages of AD. Thus, the identification of markers of conversion from prodromal form to clinically AD may be crucial for developing strategies of early interventions. The current available markers, including volumetric magnetic resonance imaging (MRI), positron emission tomography (PET), and cerebral spinal fluid (CSF) analysis are expensive, poorly available in community health facilities, and relatively invasive. Taking into account its low cost, widespread availability and non-invasiveness, electroencephalography (EEG) would represent a candidate for tracking the prodromal phases of cognitive decline in routine clinical settings eventually in combination with other markers. In this scenario, the present paper provides an overview of epidemiology, genetic risk factors, neuropsychological, fluid and neuroimaging biomarkers in AD and describes the potential role of EEG in AD investigation, trying in particular to point out whether advanced analysis of EEG rhythms exploring brain function has sufficient specificity/sensitiv ity/accuracy for the early diagnosis of AD.
dc.description.sponsorshipH2020 Marie S. Curie ITN-ETN project Turkish Academy of Sciences (TUBA), Turkey, The Young Scientists Award Programme (GEBIP) Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)en_US
dc.identifier.citationRossini, P. M., Di Iorio, R., Vecchio, F., Anfossi, M., Babiloni, C., Bozzali, M. ... Dubois, B. (2020). Early diagnosis of Alzheimer's disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts. Clinical Neurophysiology, 131(6), 1287-1310. https://dx.doi.org/10.1016/j.clinph.2020.03.003
dc.identifier.doi10.1016/j.clinph.2020.03.003
dc.identifier.endpage1310
dc.identifier.issn1388-2457
dc.identifier.issn1872-8952
dc.identifier.issue6
dc.identifier.scopusqualityQ1
dc.identifier.startpage1287
dc.identifier.urihttps://dx.doi.org/10.1016/j.clinph.2020.03.003
dc.identifier.urihttps://hdl.handle.net/20.500.12511/5622
dc.identifier.volume131
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Ireland Ltd.
dc.relation.ispartofClinical Neurophysiologyen_US
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAlzheimer's Disease
dc.subjectMild Cognitive Impairment
dc.subjectDementia
dc.subjectAD Biomarkers
dc.subjectEEG Analysis
dc.subjectEEG Rhythms
dc.subjectEvent-Related Responses
dc.subjectEarly Diagnosis
dc.titleEarly diagnosis of Alzheimer's disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts
dc.typeReview Article

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Guntekin, Bahar-2020.pdf
Boyut:
1.3 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Diğer Yayınlar Koleksiyonu
Diğer Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu